Bonus Sessions

ACG Annual Scientific Meeting Bonus Sessions

Add this optional package to your Annual Scientific Meeting registration for even more first-class education that provides an additional 16 hours of CME/MOC credit! This add-on provides access to dozens of recorded presentations and slides from 16 Bonus Sessions (listed below). These Bonus Sessions are pre-recorded narrations by faculty of their presentation slides, and will be available to watch on-demand on the ACG 2024 Conference Platform, from October until March 31, 2025. (You must register for the Annual Scientific Meeting in order to purchase the optional Annual Scientific Meeting Bonus Sessions package. Both in-person and virtual registrants can purchase this add-on package.)

In-Person GI Ignite Breakfast Sessions (BONUS SESSIONS)

NEW FORMAT! “GI Ignite – Meet the Experts” Breakfast Sessions

Join ACG expert faculty at a fun and fast-paced “GI Ignite – Meet the Experts” Breakfast Session! Offered on Monday and Tuesday mornings for in-person attendees, these small setting events allow for heightened interaction with Annual Scientific Meeting Bonus Session presenters. The first half of each 60-minute session consists of 6 expert faculty providing brief summaries of their presentations. The remaining time will be devoted to Q&A and interaction with the faculty. Coffee and continental breakfast will be provided. These sessions are open to all in-person attendees, but access to the recorded lectures and slides that will be discussed requires purchase of the ACG Annual Meeting Bonus Sessions package.

Monday, October 28, 2024 | 6:45 AM - 7:45 AM (EASTERN TIME)
GI IGNITE SESSION 1
Moderator: Neil H. Stollman, MD, FACG
Bonus Session A: Colon Poopourri
  • Checkpoint Inhibitor-Induced Colitis: Managing Refractory Cases
    Yinghong Wang, MD, PhD
    Outline management strategies for patients failing steroids and anti-TNF therapy.
  • Future of Fecal Microbiota Transplantation and Live Biotherapeutics
    Paul Feuerstadt, MD, FACG
    Discuss the pragmatic use of FMT in the near future, aside from C. difficile infection, in treating colonic disorders such as IBD, IBS, etc.
  • When and What to Test for Diarrhea: Focus on Stool Testing
    Michael Camilleri, MD, MACG
    Illustrate when to employ stool testing, and what to test for, to help manage GI diseases.
Bonus Session B: Decoding Anorectal Dysmotility
  • Anorectal Manometry and Defecography – Who Should You Refer for What Tests?
    Gregory S. Sayuk, MD, MPH
    Discuss indications for anorectal manometry and XR/MR defecography imaging (prolapse, intussusception, rectocele, etc.), the nuances of each, and how to use the results.
  • Difficult to Treat Constipation – What’s New?
    Darren M. Brenner, MD, FACG
    Explain the new constipation medications and treatments that are in the pipeline or recently approved.
  • Anorectal Dysmotility and Pain
    Leila Neshatian, MD, MSc
    Describe symptoms, diagnosis, and management of pelvic floor dyssynergia, levator ani, anismus, proctalgia, and fecal incontinence.
GI IGNITE SESSION 2
Moderator: Seth A. Gross, MD, FACG
Bonus Session C: Artificial Intelligence
  • AI for Maximizing Polyp Detection
    Seth A. Gross, MD, FACG
    Highlight AI use in polyp detection during colonoscopy and how it can benefit both your patients and practice.
  • Legal and Ethical Issues With AI
    Andrew D. Feld, MD, JD, FACG
    Identify potential legal and ethical issues with AI use, including privacy and HIPAA compliance.
  • AI to Optimize Documentation
    Nasim Parsa, MD
    Describe how AI can be used for documentation in the endoscopy suite and the clinic.
Bonus Session D: Protecting the Endoscopist
  • Radiation Safety for Endoscopists
    Nazia Hasan, MD
    Review recent best practice recommendations on minimizing procedural radiation utilization and exposure risk to patients and staff.
  • Ergonomics and Endoscopy: Optimizing Room Set-Up and Patient Positioning
    Amandeep K. Shergill, MD, MS, FACG
    Identify key interventions in room design, set-up, and patient positioning to reduce physical stress and prevent endoscopy-related injuries.
  • Best Practices in Documentation and Adverse Event Management to Minimize Litigation Risk
    Megan A. Adams, MD
    Discuss documentation and patient management strategies to enhance patient satisfaction and minimize legal repercussions.
GI IGNITE SESSION 3
Moderator: Costas H. Kefalas, MD, MMM, FACG
Bonus Session E: Environmental Sustainability in GI
  • Economic and Environmental Burden of Endoscopy
    Swapna Gayam, MD, FACG
    Discuss the financial and environmental impacts of current endoscopic practices.
  • GI Implications of Climate Change
    Rabia A. de Latour, MD
    Identify the ways that climate change impacts a variety of digestive health conditions.
  • Mitigating Environmental Effects of GI: Who Are the Stakeholders and How Can They Help?
    Nitin K. Ahuja, MD, MS
    Identify strategies that various stakeholders can adopt to reduce the environmental impact of GI procedures.
Bonus Session F: Practice Management
  • The Looming GI Physician Workforce Shortage
    Steven L. Carpenter, MD, FACG
    Describe the challenges created by the reduced GI physician workforce and increased patient demand.
  • Physician Recruitment and Retention
    Dominique E. Howard, MD, FACG
    Compare various methods of physician recruitment and retention.
  • Improving Your Practice Capacity: Advanced Practice Providers (APPs), the Patient Portal, and EHR Tips/Tricks
    Sarah M. Enslin, PA-C
    Recognize the various roles APPs may serve on the patient care team, as well as how EHRs can enhance practice efficiency.
GI IGNITE SESSION 4
Moderator: Jill K. J. Gaidos, MD, FACG
Bonus Session G: Practical Guide for IBD Activity and Therapy Monitoring
  • We Just Started a New Treatment: When, What, and How for Disease Activity Monitoring
    Jana G. Al Hashash, MD, MSc, FACG
    Summarize recommended strategies for disease activity assessments including diagnostic testing options, considerations of costs, and access to care.
  • How Often Should I Be Getting Blood Work? Guidance for Monitoring Lab Abnormalities With the Newer Advanced Therapies
    Eugene F. Yen, MD, MBA, FACG
    Outline recommendations for monitoring the newer advanced therapies for IBD including sphingosine-1-receptor agonists, JAK inhibitors, and interleukin-antagonists, and address potential lab abnormalities.
  • When Do We Stop the Treatment? Recognizing and Managing Adverse Effects Associated With Advanced Therapies
    Gary R. Lichtenstein, MD, FACG
    Explain the adverse effects of the newer advanced therapies for IBD, and when to recommend discontinuing, pausing, or continuing therapy.
Bonus Session H: Improving Health Equity in IBD
  • Current Disparities in IBD Care: How to Close the Gaps
    Adjoa Anyane-Yeboa, MD, MPH
    Describe the literature on disparities in care in the IBD patient population including the financial toxicity of IBD care, with an emphasis on creating awareness and proposing solutions to help narrow the gaps.
  • IBD in the LGBTQIA+ Community
    Victor Chedid, MD
    Highlight the specific needs of IBD patients who are part of the LGBTQIA+ community, with a focus on strategies for optimizing patient care.
  • Remote Control: IBD Care in Rural Communities
    Corey A. Siegel, MD, MS
    Summarize what is known and unknown for optimizing care for IBD patients who do not live near IBD centers, and outline best practices for ensuring appropriate care.
Tuesday, October 29, 2024 | 7:15 AM - 8:15 AM (EASTERN TIME)
GI IGNITE SESSION 5
Moderator: William D. Chey, MD, FACG
Bonus Session I: Endoscopic Challenges in the Esophagus
  • Blood, Sweat, and Mucosal Tears
    J. Andy Tau, MD
    Identify novel and emerging treatment modalities for complex esophageal endoscopic emergencies.
  • Taking It to the Top: Webs, Bars, and Pouches, Oh My!
    Ryan J. Law, DO
    Evaluate endoscopic treatments of the upper esophagus and upper esophageal sphincter disorders.
  • Management of Refractory Strictures
    Vanessa M. Shami, MD, FACG
    Summarize treatment options for refractory esophageal strictures.
Bonus Session J: NEW ACG Guidelines for the Upper GI Tract
  • ACG Guidelines for the Management of Gastric Premalignant Conditions
    Douglas R. Morgan, MD, MPH, FACG
    Summarize the indications for endoscopic surveillance of gastric intestinal metaplasia.
  • ACG-ASGE Quality Indicators for Upper Endoscopy
    Rena H. Yadlapati, MD, MSHS, FACG
    Outline the changes in the updated esophagogastroduodenoscopy QI summary.
  • ACG Guidelines for the Management of H. pylori Infection
    William D. Chey, MD, FACG
    Describe the use of antimicrobial resistance testing in the management of H. pylori infection.
GI IGNITE SESSION 6
Moderator: Amy S. Oxentenko, MD, FACG
Bonus Session K: Navigating Common Career Speed Bumps
  • I Wish I Had Said Something: Microaggressions in Medicine
    Lavanya Viswanathan, MD, MS, FACG
    Discuss the significant negative impact that microaggressions can have on career satisfaction, and how to confidently and professionally handle them in real time.
  • Finding Mentorship, Sponsorship, and Allyship After Training
    Patrick E. Young, MD, FACG
    Describe mentorship, sponsorship, and allyship, and how to secure each one after the training years.
  • At a Career Crossroads: Practical Advice on Changing Directions
    Amy S. Oxentenko, MD, FACG
    Outline steps involved in making a career pivot, such as changing from private practice to academics or from a traditional work model to a hybrid model.
Bonus Session L: Wellness for the GI Clinician
  • The Importance of Wellness
    Richard S. Bloomfeld, MD, FACG
    Discuss the key aspects of wellness and how they can contribure to increased quality of life for practitioners.
  • What Can a Director of Joy and Wellness Do for Providers?
    Jonathan A. Leighton, MD, FACG
    Develop ways to incorporate joy and wellness into your everyday practice and life.
  • Embracing Access and Establishing Boundaries in Patient Portals
    Sara N. Horst, MD, MPH, FACG
    Establish reasonable boundaries with your patients and clinical care team.
GI IGNITE SESSION 7
Moderator: Millie D. Long, MD, MPH, FACG
Bonus Session M: Therapeutic Endoscopy Literature Updates From 2023-2024
  • Pancreaticobiliary Endoscopy Literature Review
    Jennifer L. Maranki, MD
    Discuss recent key literature and high-yield, practice-impacting articles about pancreaticobiliary endoscopy from the past year.
  • Advanced Endoscopic Resection Literature Review
    Moamen Gabr, MD
    Explain recent key literature and high-yield practice-impacting articles from the past year involving advanced endoscopic resection techniques including EMR, ESD, and FTRD.
  • Obesity Literature Review
    Danny Issa, MD
    Describe recent key literature and high-yield, practice-impacting articles from the past year in obesity management, including endoscopic and pharmacologic treatments.
Bonus Session N: Pearls From the Guidelines
  • Appropriate and Tailored Polypectomy: Expert Review
    Andrew P. Copland, MD
    Describe appropriate polypectomy techniques and when tertiary referral for difficult polypectomies should be considered.
  • Risk Stratification for Colorectal Cancer Screening and Polypectomy Surveillance
    Aasma Shaukat, MD, MPH, FACG
    Outline how to stratify colon cancer risk and implement the appropriate interval for post-polypectomy surveillance.
  • Anal Cancer Screening
    Jessica D. Korman, MD
    Discuss the recent guidelines on anal cancer screening and the use of high-resolution anoscopy.
GI IGNITE SESSION 8
Moderator: Renee L. Williams, MD, MHPE, FACG
Bonus Session O: Steatotic Liver Disease
  • Incorporating Non-Invasive Tools for Staging and Risk Stratification in Patients With MASLD/MASH
    Norah A. Terrault, MD, MPH, FACG
    Outline the different blood-based and imaging-based modalities for disease staging and risk stratification in patients with MASLD/MASH.
  • MASLD/MASH: Updates in Nomenclature and Therapeutic Approaches
    Rohit Loomba, MD
    Summarize the updated steatotic liver disease nomenclature and current/new therapies for MASLD/MASH.
  • Pharmacologic Therapy for Alcohol Use Disorder and Alcohol-Associated Liver Disease
    Haripriya Maddur, MD
    Identify available therapies for alcohol use disorder and alcohol-associated liver disease.
Bonus Session P: Colorectal Cancer Screening in 2024
  • CRC Screening in 45-49-Year-Olds: How To Get It Done!
    Renee L. Williams, MD, MHPE, FACG
    Illustrate the changes in colon cancer epidemiology and how to increase participation among groups with lower rates of screening.
  • Delphi Initiative for Early-Onset CRC: DIRECt Guidelines
    Charles J. Kahi, MD, MSc, FACG
    Discuss assessment, screening, and management of early-onset colorectal cancer.
  • Noninvasive CRC Screening: It’s Here, Now What?
    Mark B. Pochapin, MD, FACG
    Summarize noninvasive tests for colon cancer screening, including their role and timing within the screening algorithm.
View Wednesday Agenda